Stockreport

Benitec Biopharma: OPMD Program Continues To Advance With Catalysts [Seeking Alpha]

Benitec Biopharma Inc.  (BNTC) 
US:NASDAQ Investor Relations: benitec.com/for-investors/investor-faqs
PDF Play 10min Summary Benitec Biopharma Inc.'s BB-301 showed positive interim results in treating OPMD, allowing for higher dosing in 2025 and a potential late-stage [Read more]